EVALUATION OF TYPE 2 DIABETES TREATMENT IN RUSSIA OVER THE PAST FIVE YEARS

Publication date: 30 may 2018

Aston Health in conjunction with Endocrinology Research Center conducted a research to find out what drug treatments were commonly used in patients with type 2 diabetes (T2DM) in Russia over the period 2013-2017.

It was found that oral glucose-lowering medications were prescribed most often (typically as monotherapy) and the overall share of patients receiving oral drug therapy has grown by 15.2% over the specified period.

The most frequently prescribed glucose-lowering agents were biguanides and sulfonylurea derivatives. Other classes of medications increasingly used in treatment of T2DM include DPP4i and SGLT2 (mainly as combination therapy). Despite an increase in prescribing of insulin therapy (by 5%), the number of patients treated with insulin does not exceed 20% of the total patient population with T2DM.

The proportion of patients with diabetes not receiving any drug therapy continues to decline steadily, which reflects overall improvement in the diabetes care. Both the wider use of the registry of patients with T2DM and the introduction of the newest clinical guidelines for prescribing/administration of treatment at disease onset has played a substantial part in it.

Classes of medications prescribed for T2DM in 2013-2017 include: 
• Monotherapy: biguanides and sulfonylurea derivatives
• Combination therapy: biguanides + sulphonylurea and biguanides + DPP-4 inhibitors
• Combination therapy: biguanides + sulphonylurea + DPP-4 inhibitors and biguanides + sulphonylurea + SGLT2

In 2017, the number of patients with T2DM in this country reached 3.9 million people. The research was ordered by the Ministry of Health and utilized the database of the National Registry of Diabetes, which covers 81 regions of Russia.

The National Registry of Diabetes is maintained by the Endocrinology Research Center; the technical support is provided by Aston Health using proprietary technology platform Quinta®. Aston is also responsible for registry user training.